You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

~ Buy the NULIBRY (fosdenopterin hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

NULIBRY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nulibry patents expire, and when can generic versions of Nulibry launch?

Nulibry is a drug marketed by Sentynl Theraps Inc and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in ten countries.

The generic ingredient in NULIBRY is fosdenopterin hydrobromide. One supplier is listed for this compound. Additional details are available on the fosdenopterin hydrobromide profile page.

DrugPatentWatch® Generic Entry Outlook for Nulibry

Nulibry will be eligible for patent challenges on February 26, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 26, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for NULIBRY
International Patents:10
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for NULIBRY
What excipients (inactive ingredients) are in NULIBRY?NULIBRY excipients list
DailyMed Link:NULIBRY at DailyMed
Drug patent expirations by year for NULIBRY
Drug Prices for NULIBRY

See drug prices for NULIBRY

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NULIBRY
Generic Entry Date for NULIBRY*:
Constraining patent/regulatory exclusivity:
INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NULIBRY

US Patents and Regulatory Information for NULIBRY

NULIBRY is protected by one US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NULIBRY is ⤷  Try a Trial.

This potential generic entry date is based on INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NULIBRY

Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A

FDA Regulatory Exclusivity protecting NULIBRY

INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
Exclusivity Expiration: ⤷  Try a Trial

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM STUDY ORGN001-102
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NULIBRY

See the table below for patents covering NULIBRY around the world.

Country Patent Number Title Estimated Expiration
Germany 102004004642 Produktion, Gewinnung und therapeutischer Einsatz des Molybdopterin-Derivats Precursor Z zur Therapie der Stoffwechselerkrankung humaner Molybdäncofaktor-Defizienz und anderer assoziierter Krankheiten ⤷  Try a Trial
Poland 1664317 ⤷  Try a Trial
European Patent Office 1664317 Utilisation du précurseur Z pour produire un agent servant à traiter la déficience humaine en cofacteur molybdène (Use of precursor Z for the production of a means for therapy of human molybdenum cofactor deficiency) ⤷  Try a Trial
Spain 2406733 ⤷  Try a Trial
Cyprus 1113960 ⤷  Try a Trial
Denmark 1664317 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2005073387 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.